The media coverage surrounding tennis legend Chris Evert’s third bout with ovarian cancer follows a predictable, deeply flawed script.
The narrative is always the same. A beloved athlete faces a brutal recurrence, the public pours out sympathy, and the articles end with a well-meaning but fundamentally dangerous piece of advice: “Get screened early.”
It sounds logical. In almost every other facet of health, early detection is the holy grail. But in the cold, hard world of gynecologic oncology, pushing for mass ovarian cancer screening isn't just misguided. It is a statistical and medical failure that the establishment refuses to admit.
The lazy consensus insists that if we just test more women, we can stop this disease. The brutal reality? We do not have a reliable screening test for ovarian cancer, and pretending we do is actively harming women.
The Myth of the Early Warning System
When Evert was first diagnosed in 2021, it was discovered during a preventive hysterectomy after her sister, Jeanne Evert Dubin, died of the same disease. Evert possessed the BRCA1 gene mutation, a known genetic accelerator for breast and ovarian malignancies. Her subsequent recurrences in 2023 and late 2025 highlight the relentless nature of the disease.
But the media weaponizes these high-profile tragedies to scold the general public into demanding transvaginal ultrasounds and CA-125 blood tests.
This is where the math falls apart.
The CA-125 test measures a specific protein in the blood. The medical establishment knows—yet rarely broadcasts—that CA-125 is a notoriously unspecific biomarker. It spikes for a dozen benign reasons: endometriosis, uterine fibroids, pelvic inflammatory disease, or even a normal menstrual cycle.
When you apply a poorly specific test to a relatively rare cancer in the general population, Bayes' theorem takes over. The vast majority of positive results will be false alarms.
Imagine a scenario where 10,000 women undergo routine CA-125 screening. Hundreds will return elevated levels. These women are then funneled into a pipeline of escalating medical anxiety, leading to exploratory laparoscopies and major surgeries to remove perfectly healthy ovaries.
The data back this up. The massive UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), which watched over 200,000 women for more than 16 years, delivered a crushing blow to the screening advocates. The study concluded that while screening did pick up some cancers slightly earlier, it failed to reduce mortality.
Women in the screening group died at the exact same rate as women in the unscreened group. They just spent more of their remaining years living as cancer patients, enduring surgeries they might never have needed.
The BRCA Illusion: Normalizing the Exception
The media treats Chris Evert’s medical timeline as a blueprint for the average woman. This is a massive epidemiological error.
Evert is a BRCA1 carrier. That changes the math entirely. For a woman with a BRCA1 mutation, the lifetime risk of developing ovarian cancer climbs to somewhere between 35% and 60%. For the general population, that lifetime risk sits at a tiny 1.3%.
Using the medical strategy of a high-risk BRCA carrier to guide the health decisions of the general public is like forcing every driver on the highway to wear a professional racing helmet because Formula 1 drivers need them.
For the average woman, asymptomatic screening does not save lives; it invents patients.
True expertise means knowing the limits of your tools. I have watched clinicians order pelvic ultrasounds for vague bloating in low-risk 35-year-old women, only to find a benign fluid-filled cyst. What happens next? Panic. Repeat scans. Consultations with specialists. Eventually, a surgery that introduces scar tissue, surgical risks, and immense psychological trauma. All to find absolutely nothing.
The downside to our contrarian approach is obvious: it feels passive. It forces us to accept that we cannot control everything through a simple annual blood draw. Human nature craves action, even if that action is actively detrimental.
Dismantling the Flawed Premise
If you look at the most common questions floating around the internet regarding this topic, the collective misunderstanding becomes even clearer.
Why isn't there a routine pap smear for ovarian cancer?
This question assumes that because the Pap smear successfully reduced cervical cancer rates, a similar scrape-and-look test must exist for the ovaries. It fundamentally misunderstands anatomy. Cervical cancer occurs on the surface of the cervix, easily accessible during a routine exam. Ovarian cancer begins deep within the pelvis—often, as modern pathology shows, starting in the microscopic fimbriae at the tips of the fallopian tubes, not the ovaries themselves. You cannot scrape the fallopian tubes during an office visit.
Can pelvic exams detect ovarian cancer early?
Brutally honest answer: No. By the time an ovarian mass is large enough for a physician to physically palpate during a standard bimanual pelvic exam, the disease is almost certainly advanced. The U.S. Preventive Services Task Force (USPSTF) explicitly recommends against screening for ovarian cancer in asymptomatic women using pelvic exams for this exact reason. It provides a false sense of security while offering zero diagnostic utility.
The Actionable Pivot: What to Do Instead
Stop demanding useless screening tests that the data proved do not work. If you want to actually mitigate risk based on real clinical frameworks, change the strategy entirely.
- Map the Real Lineage: Do not look for vague symptoms; look at the family tree. Genetic testing for BRCA1, BRCA2, and Lynch syndrome is highly effective. If you have a first-degree relative (mother, sister) who had ovarian or early-onset breast cancer, skip the standard OB-GYN screening chat and go straight to a genetic counselor.
- The Power of Suppression: For women in the general population, the most effective tool against ovarian cancer isn't detection—it’s prevention. Using oral contraceptives (birth control pills) for five consecutive years reduces the lifetime risk of ovarian cancer by roughly 50%. It halts ovulation, preventing the constant microscopic tearing and repairing of the ovarian surface that can trigger malignant transformations.
- Rethink the Fallopian Tubes: If you are undergoing a pelvic surgery for other reasons—like a tubal ligation or fibroid removal—talk to your surgeon about an opportunistic salpingectomy (removing the fallopian tubes while leaving the ovaries intact). Because a massive percentage of high-grade serous ovarian cancers actually originate in the tubes, this single surgical pivot slashes risk without throwing you into premature menopause.
The hard truth about Chris Evert’s situation is that her recurrence isn't a failure of her personal vigilance. She did everything right. She had the surgeries, she took the therapies, and she monitored her health with the best medical minds on earth.
Her cancer returned because high-grade serous ovarian cancer is an aggressive, biologically complex monster that hides at the cellular level, long after a surgeon thinks they cleared the margins.
Stop letting the health media convince you that an annual checkup can catch everything if you just try hard enough. Ovarian cancer screening for the masses is a ghost. Stop chasing it, look at the actual genetic data, and start focusing on prevention strategies that actually move the needle.
